Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lung Neoplasms × Pregnancy Tests × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 2 Uterine Neoplasms 1 Uterine Diseases 1 Uterine Cervical Neoplasms 1 Uterine Cervical Dysplasia 1 Uterine Cervical Diseases 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Spondylarthritis 1 Precancerous Conditions 1 Papillomavirus Infections 1 Neuroblastoma 1 Neoplasms by Site 1 Myelodysplastic Syndromes 1 Lung Neoplasms 1 Leukemia, Myeloid, Acute 1 Genital Neoplasms, Female 1 Genital Diseases, Female 1 Genital Diseases 1 Female Urogenital Diseases and Pregnancy Complications 1

Interventions

Carboplatin 295 Cisplatin 218 Radiotherapy 177 Paclitaxel 174 Pemetrexed 165 Docetaxel 156 Gemcitabine 139 pembrolizumab 126 Erlotinib Hydrochloride 98 Etoposide 89 Magnetic Resonance Spectroscopy 83 Bevacizumab 75 Specimen Handling 67 durvalumab 64 Radiosurgery 63 Nivolumab 63 Vinorelbine 50 Drug Therapy 46 osimertinib 45 Gefitinib 42 Irinotecan 37 Biopsy 36 Topotecan 35 Radiation 35 Cyclophosphamide 35 atezolizumab 34 Standard of Care 33 Cetuximab 31 Blood Specimen Collection 30 Immunoglobulin G 26

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06620835 2025-07-29

OPTALK

Groupe Francais De Pneumo-Cancerologie

Phase 2 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡